About

Julia Maltzman, M.D., has served as Adicet Bio's Chief Medical Officer since January 2025. She previously served as Chief Medical Officer of IconOVir Bio from September 2022 to January 2025, leading a clinical development program focused on refractory solid tumors.

Before that she held leadership roles at Roche/Genentech, as VP and Global Head of GI Cancers and Cancer Immunotherapy and earlier as Group Medical Director, Cancer Immunotherapy. She received her M.D. from the University of Colorado, completed her internship and residency in Internal Medicine at the University of Chicago, and completed a fellowship in Hematology/Oncology at the University of Pennsylvania. She holds a B.A. in Political Science from the University of Colorado.

Roles

Adicet Bio, Inc.
Chief Medical Officer · Current role
2025–present
IconOVir Bio, Inc.
Chief Medical Officer · Led design and execution of a clinical development program focused on refractory solid tumors.
2022-2025
Roche/Genentech, Inc.
VP, Global Head of GI Cancers and Cancer Immunotherapy · Previously Group Medical Director, Cancer Immunotherapy from 2018 to 2020.
2020-2022

Fixed Compensation

FY 2025
Base salary
$452,308
All other compensation
$16,290
401(k) match$15,750
phone allowance$540

Performance Compensation

Data from FY 2025

Cash incentive

Non-equity incentive plan compensation
$153,600

Stock awards

Option awards (grant-date fair value)
$502,605

Also at Adicet Bio, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.